Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 14, Pages -Publisher
MDPI
DOI: 10.3390/ijms22147518
Keywords
soft tissue sarcoma; genetic landscape; immune profiling; tumor microenvironment; immunotherapy; targeted therapy; epigenetics; combination therapy
Funding
- Italian Ministry of Health [RF-2016-02362609]
- Italian Ministry of Health-Institutional grant [BRI2017]
- Fondazione IRCCS
Ask authors/readers for more resources
Soft tissue sarcomas are rare malignant tumors with various histologies. Current therapies for metastatic STS have limited efficacy, but immune hot tumor microenvironments are observed across different histologies, suggesting potential response to immunotherapy. Fine characterization of STS at different levels is needed to identify predictive biomarkers for immunotherapy and targetable pathways for immune cold tumors.
Soft tissue sarcomas (STSs) are a family of rare malignant tumors encompassing more than 80 histologies. Current therapies for metastatic STS, a condition that affects roughly half of patients, have limited efficacy, making innovative therapeutic strategies urgently needed. From a molecular point of view, STSs can be classified as translocation-related and those with a heavily rearranged genotype. Although only the latter display an increased mutational burden, molecular profiles suggestive of an immune hot tumor microenvironment are observed across STS histologies, and response to immunotherapy has been reported in both translocation-related and genetic complex STSs. These data reinforce the notion that immunity in STSs is multifaceted and influenced by both genetic and epigenetic determinants. Cumulative evidence indicates that a fine characterization of STSs at different levels is required to identify biomarkers predictive of immunotherapy response and to discover targetable pathways to switch on the immune sensitivity of immune cold tumors. In this review, we will summarize recent findings on the interplay between genetic landscape, molecular profiling and immunity in STSs. Immunological and molecular features will be discussed for their prognostic value in selected STS histologies. Finally, the local and systemic immunomodulatory effects of the targeted drugs imatinib and sunitinib will be discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available